Union européenne - français - EMA (European Medicines Agency)

roche registration limited - emicizumab - hémophilie a - antihémorragiques - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra peut être utilisé dans tous les groupes d'âge.

Canada - français - Health Canada

hoffmann-la roche limited - Émicizumab - solution - 30mg - Émicizumab 30mg - antihemorrhagic agents, miscellaneous

Canada - français - Health Canada

hoffmann-la roche limited - Émicizumab - solution - 60mg - Émicizumab 60mg - antihemorrhagic agents, miscellaneous

Canada - français - Health Canada

hoffmann-la roche limited - Émicizumab - solution - 105mg - Émicizumab 105mg - antihemorrhagic agents, miscellaneous

Canada - français - Health Canada

hoffmann-la roche limited - Émicizumab - solution - 150mg - Émicizumab 150mg - antihemorrhagic agents, miscellaneous

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - emicizumabum - solution injectable - emicizumabum 30 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 1 ml. - l'hémophilie a - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - emicizumabum - solution injectable - emicizumabum 60 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 0.4 ml. - l'hémophilie a - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - emicizumabum - solution injectable - emicizumabum 105 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 0.7 ml. - l'hémophilie a - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - emicizumabum - solution injectable - emicizumabum 150 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 1 ml. - l'hémophilie a - biotechnologika